programmed cell death 1 knockout epstein-barr virus-specific cytotoxic t lymphocytes

Programmed cell death 1 knockout epstein-barr virus-specific cytotoxic t lymphocytes is an investigational adoptive cell therapy currently in clinical development for the treatment of EBV-associated malignancies. The therapy consists of cytotoxic T lymphocytes (CTLs) that are naturally specific to Epstein-Barr virus (EBV) antigens (such as LMP1, LMP2, and EBNA1) and have been further modified ex vivo using CRISPR/Cas9 gene-editing technology to knockout the PDCD1 gene, which encodes the Programmed cell death protein 1 (PD-1) receptor. PD-1 is a key immune checkpoint that typically limits T-cell activity when it binds to its ligands (PD-L1/PD-L2) in the tumor microenvironment. By eliminating PD-1 expression, these CTLs are rendered resistant to checkpoint-mediated inhibition, theoretically enhancing their persistence, expansion, and antitumor efficacy against EBV-positive tumor cells in conditions like nasopharyngeal carcinoma, Hodgkin lymphoma, and gastric cancer.

Other names

PD-1 knockout EBV-CTLsPD1 knockout EBV-CTLsPD 1 knockout EBV-CTLsPD-1 knockout EBV-specific T cellsPD1 knockout EBV-specific T cellsPD 1 knockout EBV-specific T cellsPD-1-knockout EBV-specific cytotoxic T lymphocytesPD1-knockout EBV-specific cytotoxic T lymphocytesPD 1-knockout EBV-specific cytotoxic T lymphocytesCRISPR-edited PD-1 knockout EBV-CTL